Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by introducing a new pembrolizumab combination expansion cohort.
CB307 is a groundbreaking CD137 x PSMA bispecific designed to prolong its half-life and enhance T cell response to cancer without causing systemic toxicity. The ongoing Phase 1b clinical trial for CB307 is already underway in individuals with metastatic castration-resistant prostate cancer (mCRPC) as a last-line treatment option. With the inclusion of the pembrolizumab combination expansion cohort, researchers hope to gain further insight into the effectiveness of CB307 when used alongside pembrolizumab.
The additional financing obtained will allow Crescendo to expedite the clinical development of CB307. Both preclinical data generated by Crescendo